Current status of DILD in molecular targeted therapies-Reference-Cited by-同舟云学术

Current status of DILD in molecular targeted therapies

Published:2012-11-15 Issue:6 Volume:17 Page:534-541
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Saito Yoshinobu,Gemma Akihiko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-012-0494-5.pdf

Reference31 articles.

1. Inoue A, Saijo Y, Maemondo M et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139

2. Pharmaceuticals and Medical Devices Agency (2004), Reports on Iressa Tablets 250 prospective study (special investigation). In: Pharmaceuticals and Medical Devices Safety Information. No. 206 October 2004. http://www.pmda.go.jp/english/service/pdf/precautions/PMDSI-206.pdf . Accessed Oct 2012

3. Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348–1357

4. Kubota K, Nishiwaki Y, Tamura T et al (2008) Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 3:1439–1445

5. Nakagawa K, Kudoh S, Ohe Y et al (2012) Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 7:1296–1303

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis;Journal of Nippon Medical School;2024-04-25

2. Understanding Drug-Induced Lung Injuries;Analysis File of Drug-Induced Lung Injury;2024

3. Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection;Expert Review of Respiratory Medicine;2022-10-03

4. Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges;ERJ Open Research;2022-04

5. Chemotherapy-Associated Pulmonary Toxicity—Case Series from a Single Center;South Asian Journal of Cancer;2021-11-11